Home > EMA review finds AstraZeneca benefits still outweigh risks

News
EMA review finds AstraZeneca benefits still outweigh risks

Description

The deputy executive director of EU's drug watchdog says during a press conference that a review of AstraZeneca's Covid-19 vaccine found its benefits still outweigh the risks for adults despite links to blood clots. SOUNDBITE

Added on the 23/04/2021 16:35:28 - Copyright : AFPTV - First images

To customise your video :

More videos on the subject

EU agency says J&J Covid-19 vaccine's benefits outweigh the risks

Europe's medicines regulator says that blood clots should be listed as a very rare side effect of Johnson & Johnson's coron…

20/04/2021 - AFPTV - First imag…
AstraZeneca vaccine benefits increase with age: EMA

23/04/2021 - AFPTV…
AstraZeneca Covid jab positives still outweigh risks: WHO

19/03/2021 - AFPTV…
EU regulator 'firmly convinced' of AstraZeneca benefits

The EU's drug regulator says it remains "firmly convinced" of the benefits of AstraZeneca's coronavirus vaccine despite s…

16/03/2021 - AFPTV - First imag…
Review finds UN agency for Palestinians 'irrepla…

22/04/2024 - AFPTV…

News
EMA review finds AstraZeneca benefits still outweigh risks

More videos on the subject

EU agency says J&J Covid-19 vaccine's benefits outweigh the risks

AstraZeneca vaccine benefits increase with age: EMA

AstraZeneca Covid jab positives still outweigh risks: WHO

EU regulator 'firmly convinced' of AstraZeneca benefits

Review finds UN agency for Palestinians 'irrepla…

More videosNews

Ukraine: après la reprise de la ville, Zelensky...

DemainEntreprendre - épisode 12

Ouverture d'un nouveau secteur: combien de temps...

News EMA review finds AstraZeneca benefits still outweigh risks

More videos on the subject

More videosNews

News
EMA review finds AstraZeneca benefits still outweigh risks